Patents Assigned to Idec Pharmaceuticals Corporation
  • Publication number: 20080089893
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 25, 2001
    Publication date: April 17, 2008
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell Anderson, Nabil hanna, Ronald Newman, Mitchell Reff, William Rastetter
  • Patent number: 6846476
    Abstract: Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an 90Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: January 25, 2005
    Assignee: IDEC Pharmaceuticals Corporation
    Inventor: Christine White
  • Patent number: 6841383
    Abstract: A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: January 11, 2005
    Assignee: Idec Pharmaceuticals Corporation
    Inventors: Mitchell R. Reff, Richard Spence Barnett, Karen Retta McLachlan
  • Publication number: 20040258616
    Abstract: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.
    Type: Application
    Filed: January 27, 2004
    Publication date: December 23, 2004
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Karen McLachlan, Scott Glaser, Robert J. Peach, Tony Rowe
  • Publication number: 20040213784
    Abstract: The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
    Type: Application
    Filed: May 21, 2004
    Publication date: October 28, 2004
    Applicant: Idec Pharmaceuticals Corporation
    Inventors: Antonio J. Grillo-Lopez, John Leonard
  • Patent number: 6682734
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 2004
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20040005323
    Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein ≦2×10−9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
    Type: Application
    Filed: March 10, 2003
    Publication date: January 8, 2004
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventor: Peter Brams
  • Publication number: 20030235533
    Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2.
    Type: Application
    Filed: February 19, 2003
    Publication date: December 25, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Dennis Gately
  • Publication number: 20030211038
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Application
    Filed: July 16, 2002
    Publication date: November 13, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: William H. Rastetter, Christine A. White
  • Publication number: 20030206903
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Application
    Filed: May 19, 2003
    Publication date: November 6, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-Lopez
  • Publication number: 20030180290
    Abstract: Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.
    Type: Application
    Filed: November 12, 2002
    Publication date: September 25, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Kandasamy Hariharan, Nabil Hanna
  • Publication number: 20030175269
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
    Type: Application
    Filed: June 17, 2002
    Publication date: September 18, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland L. Newman
  • Publication number: 20030170233
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
    Type: Application
    Filed: June 17, 2002
    Publication date: September 11, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
  • Publication number: 20030157641
    Abstract: Described herein is a novel expression system for producing multiple gene products of interest from a single polycistronic construct. In particular, the expression system contains a polycistronic vector capable of expressing functional antibodies in eukaryotic host cells, which vector contains at least the following elements operably linked in the 5′ to 3′ orientation: a promoter operable in a eukaryotic cell; a DNA sequence encoding at least the variable region of an antibody light chain; an internal ribosome entry site (IRES); and at least one DNA sequence encoding an antibody heavy chain. Also disclosed are mammalian cells containing the polycistronic expression vector, and a method of producing functional antibodies in mammalian cells transfected with the polycistronic expression vector.
    Type: Application
    Filed: November 18, 2002
    Publication date: August 21, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Mitchell Reff, Richard Barnett
  • Publication number: 20030147885
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: September 11, 2002
    Publication date: August 7, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20030095963
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 25, 2001
    Publication date: May 22, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20030077275
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Application
    Filed: August 5, 2002
    Publication date: April 24, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • Publication number: 20030064510
    Abstract: The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: April 3, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Mitchell E. Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Marie Hardwick
  • Publication number: 20030059424
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: March 25, 2002
    Publication date: March 27, 2003
    Applicant: IDEC Pharmaceutical Corporation
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20030026804
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Application
    Filed: July 17, 2002
    Publication date: February 6, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-Lopez